Summit Therapeutics heads into its June 10 earnings report with its own executives making a conspicuous case for the stock just days before the release.
On June 4, CEO Maky Zanganeh purchased 100,000 shares at $14.60 — a $1.46 million buy — while CFO Manmeet Soni added 50,000 shares across two tranches at roughly the same price, committing around $720,000. Together, that's over $2.18 million in net insider buying in a single session, just six days before the print. The timing is notable: the stock had already shed 21% over the prior month, and the insiders stepped in near what appears to be a deliberate accumulation level rather than a routine grant-related purchase.
The analyst community is far less unified. Bernstein initiated coverage on May 22 with an Underperform and a $7.70 target — barely half the current $14.29 price — citing concern over delayed HARMONi-2 overall survival disclosure and competitive pressure from Merck's immunotherapy data. That same day, HC Wainwright downgraded to Neutral from Buy. Both moves came within the past three weeks and represent a meaningful shift in tone from a firm that had previously been one of Summit's most consistent bulls. On the other side, Stifel initiated in April with a Buy and a $45 target, and a handful of holders maintain price targets well above $20. The mean consensus target runs at $21.27, implying over 40% upside from current levels — but the distribution underneath that average is unusually wide, reflecting genuine disagreement rather than a consensus with minor dispersion.
The bear case centres on one question: when, and at what level, will ivonescimab's overall survival data arrive, and whether it can hold up against Merck's updated pembrolizumab profile. Bulls point to the 80% estimated approval probability in non-small cell lung cancer and meaningful trial probabilities across additional indications including triple-negative breast cancer and colorectal cancer. The ORTEX short score, at 74.8, remains elevated even as it has eased modestly over the past two weeks from a peak near 77.4 — signalling that short-side conviction is high but no longer accelerating. Short interest at 3.9% of free float is moderate rather than extreme, and borrowing costs have eased to around 0.73% with availability loosening sharply to 107%, so the lending market is not signalling an imminent squeeze.
Past earnings reactions at Summit have been dramatic in both directions: the May 4 print produced a one-day gain of nearly 9% and a five-day follow-through of almost 16%, while an April 30 event delivered a single-day drop of 23%. The print arriving today will test whether the insider buying cluster at $14-$15 reflects informed confidence in the data pipeline — or simply a floor that the market has yet to decide it agrees with.
See the live data behind this article on ORTEX.
Open SMMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
